Abstract
We generated a monoclonal antibody, RG-1, that binds to highly conserved L2 residues 17 to 36 and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising residues 17 to 36 (peptide 17-36) neutralized pseudoviruses HPV5, HPV6, HPV16, HPV 18, HPV31, HPV 45, HPV 52, HPV 58, bovine papillomavirus 1, and HPV11 native virions. Depletion of HPV16 L2 peptide 17-36-reactive antibodies from cross-neutralizing rabbit and human L2-specific sera abolished cross-neutralization and drastically reduced neutralization of the cognate type. This cross-neutralization of diverse HPVs associated with cervical cancer, genital warts, and epidermodysplasia verruciformis suggests the possibility of a broadly protective, peptide-based vaccine.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / biosynthesis
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Viral / administration & dosage
-
Antibodies, Viral / biosynthesis
-
Antibodies, Viral / immunology*
-
Capsid Proteins / immunology*
-
Cross Reactions
-
Human papillomavirus 16 / immunology
-
Human papillomavirus 16 / pathogenicity
-
Humans
-
Immunization, Passive
-
Mice
-
Molecular Sequence Data
-
Neutralization Tests
-
Oncogene Proteins, Viral / immunology*
-
Papillomaviridae / classification*
-
Papillomaviridae / immunology*
-
Papillomavirus Infections / prevention & control
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
Capsid Proteins
-
L2 protein, Human papillomavirus type 16
-
L2 protein, Human papillomavirus type 18
-
Oncogene Proteins, Viral